A Priori Prediction of Ligand Affinity by Energy Minimization

Perspectives in Drug Discovery and Design

Volumn 9, Issue , 1998, Pages 63-84

  Holloway, M Katharine ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001828363     PISSN: 09282866     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1027251719816     Document Type: Article

References (42)

1. Kollman, P., Free energy calculation: Applications to chemical and biochemical phenomena, Chem. Rev., 93 (1993) 2395-2417.
2. Oprea, T.I., Waller, C.L. and Marshall, G.R., 3-dimensional quantitavie structure-activity relationship of human-immunodeficiency-virus-(I) protease inhibitors: 2. Predictive power using limited exploration of alternate binding modes,. J. Med. Chem., 37 (1994) 2206-2215.
3. Waller, C.L., Oprea, T.I., Giolitti, A. and Marshall, G.R., 3-dimensional QSAR of human-immunodeficiency-virus-(I) protease inhibitors: 1. A COMFA study employing experimentally-determined alignment rules, J. Med. Chem., 36 (1993) 4152-4160.
4. Doweyko, A.M., Three-dimensional pharmacophores from binding data, J. Med. Chem., 37 (1994) 1769-1778.
5. Meng, E.C., Kuntz, I.D., Abraham, D.J. and Kellogg, O.E., Evaluating docked complexes with the HINT exponential function and empirical atomic hydrophobicities, J. Comput.-Aided Mol. Design, 8 (1994) 299-306.
6. Nauchitel, V., Villaverde, M.C. and Sussman, F., Solvent accessibility as a predictive tool for the free-energy of inhibitor binding to the HlV-1 protease, Protein Science, 4 (1995) 1356-1364.
7. Wang, H. and Ben-Naim, A., A possible involvement of solvent-induced interactions in drug design, J. Med. Chem., 39 (1996) 1531-1539.
8. Wallqvist, A., Jernigan, R.L. and Covell, D.G., A preference-based free-energy parameterization of enzyme-inhibitor binding: Applications to HlV-1 protease inhibitor design, Protein Science, 4 (1995) 1881-1903.
9. Wallqvist, A. and Covell, D.G., Docking enzyme-inhibitor complexes using a preference-based free-energy surface, Proteins: Struct., Funct. Gene., 25 (1996) 403-419.
10. Verkhivker, G., Appelt, K., Freer, S.T., and Villafranca, J.E., Empirical free energy calculations of ligand-protein crystallographic complexes: I. Knowledge-based ligand-protein interaction potentials applied to the prediction of human immunodeficiency virus 1 protease binding affinity, Protein Eng., 8 (1995) 677-691.
11. Verkhivker, G.M. and Rejto, P.A., A mean field model of ligand-protein interactions: Implications for the structural assessment of human immunodeficiency virus type I protease complexes and receptor-specific binding, Proc. Natl. Acad. Sci. USA, 93 (1996) 60-64.
12. Meng, E.G. Shoichet, B.K. and Kuntz, I.D., Automated docking with grid-based energy evaluation, J Comput. Chem., 13 (1992) 505.
13. Verlinde, C.L.M.J., Rudenko, G., and Wim, G.J.H., In search of new lead compounds for trypanosomiasis drug design: a protein structure-based linked-fragment approach, J., Comput.-Aided Mol. Design, 6 (1992) 131-147.
14. Rotstein, S.H. and Murcko, M. A., Groupbuild: A fragment-based method for de novo drug design, J. Med. Chem., 36 (1993) 1700-1710.
15. Böhm, H.-J., The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure, J. Comput.-Aided Mol. Design, 8 (1994) 243-256.
16. Bohacek, R.S.; McMartin, C., De novo design of highly diverse structures complementary to enzyme binding sites: Application to thermolysin, In Reynolds, C.H., Holloway, M.K. and Cox, H.K., (Eds.) Computer-aided molecular design: Applications in agrochemicals, materials and pharmaceuticals, ACS Symposium series 589, American Chemical Society, Washington, DC, 1995, pp. 82-97.
17. Head, R.D., Smythe, M.L., Oprea, T.I., Waller, C.L., Green, S.M. and Marshall, G.R., VALIDATE: A new method for the receptor-based prediction of binding affinities of novel ligands, J. Am. Chem. Soc., 118 (1996) 3959-3969.
18. Ortiz, A.R., Pisabarro, M.T., Gago, F. and Wade, R.C., Prediction of drug binding affinities by comparative binding energy analysis, J. Med. Chem., 38 (1995) 2681-2691.
19. Vajda, S., Weng, Z., Rosenfeld, R. and DeLisi, C., Effect of conformational flexibility and salvation on receptor-ligand binding free energies, Biochemistry, 33 (1994) 13977-13988.
20. King, B.L., Vajda, S. and Delisi, C., Empirical free-energy as a target function in docking and design: Application to HlV-1 protease inhibitors, FEBS Lett., 384 (1996) 87-91.
21. Taylor, N.R. and von Itzstein, M., Molecular modeling studies on ligand-binding to sialidase from influenza virus and the mechanism of catalysis, J. Med. Chem., 37 (1994) 616-624.
22. De Winter, H.L., and von Itzstein, M., Aldose reductase as a target for drug design-Molecular modeling calculations on the binding of acyclic sugar substrates to the enzyme, Biochemistry, 34 (1995) 8299-8308.
23. Grootenhuis, P.D.J. and van Galen, P.J.M., Correlation of binding affinities with nonbonded interaction energies of thrombin-inhibitor complexes, Acta Cryst., D51 (1995) 560-566.
24. Kurinov, I.V. and Harrison, R. W., Prediction of New Serine Proteinase Inhibitors, Structural Biology, 1 (1994) 735-743.
25. Sansom, C.E., Wu, J. and Weber, I.T., Molecular mechanics analysis of inhibitor binding to HlV-1 protease, Protein Eng., 5 (1992) 659-667.
26. Weber, I.T., Harrison, R.W., Molecular mechanics calculations on HIV-1 prolease with peptide-substrates correlate with experimental data, Protein Eng., 9 (1996) 679-690.
27. Miertus, S., Furlan. M., Tossi, A. and Romeo, D., Design of new inhibitors of HIV-1 aspartic protease, Chem. Phys., 204 (1996) 173-180.
28. Tossi, A., Furlan, M., Antcheva, N., Romeo, D. and Miertus, S., Efficient inhibition of HIV-1 aspartic protease by synthetic, computer designed peptide mimetics. Minerva Biotec., 8 (1996) 165-171.
29. Viswanadhan, V.N., Reddy, M.R., Wlodawer, A., Varney. M.D. and Weinstein, J.N., An approach to rapid estimation of relative binding affinities of enzyme inhibitors: Application to peptidomimetic inhibitors of the human immunodeficiency virus type I protease, J. Med. Chem., 39 (1996) 705-712.
30. Holloway, M.K., Wai, J.M., Halgren, T.A., Fitzgerald, P.M.D., Vacca, J.P., Dorsey, B.D., Levin, R. B., Thompson, W.J., Chen, L.J., Desolms, S.J., Gaffin, N., Ghosh, A.K., Giuliani, E.A., Graham, S.L., Guare, J.P., Hungate, R.W., Lyle, T.A., Sanders, W.M., Tucker, T.J., Wiggins, M., Wiscount, C.M., Woltersdorf, O.W., Young, S.D., Darke, P.L., and Zugay, J.A., A priori prediction of activity for HlV-1 protease inhibitors employing energy minimization in the active site, J. Med. Chem., 38 (1995) 305-317.
31. Holloway, M.K. and Wai, J.M., Structure-based design of human immunodeficiency virus-1 protease inhibitors: Correlating calculated energy with activity, In Reynolds, C.H., Holloway, M.K., and Cox, H.K. (Eds.) Computer-aided molecular design: Applications in agrochernicals, materials, and pharmaceuticals, ACS Symposium series 589, American Chemical Society, Washington, DC, 1995, pp. 36-50.
32. Thompson, W.J., Fitzgerald, P.M.D., Holloway, M.K., Emini, E.A., Darke, P.L., McKeever, B.M., Schleif, W.A., Quintero, J.C., Zugay, J.A., Tucker, T.J., Schwering, J.E., Homnick, C.F., Nunberg, J., Springer, J.P. and Huff, J.R., Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1, phenyl sustituents: X-ray crystal structure assisted design, J. Med. Chem., 35 (1992) 1685-1701.
33. Hofmann, T., Hodges, R.S. and James, M.N.G., Effect of pH on the activities of Penicillopepsin and Rhizopus pepsin and a proposal for the productive substrate binding mode in Penicillopepsin, Biochemistry, 23 (1984) 635-643.
34. Hyland, L.J., Tomaszek, T.A., Jr. and Meek, T.D., Human immunodeficiency virus-1 protease: 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism, Biochemistry, 30 (1991) 8454-8463.
35. CHARMm version 21.1.7b.; available from Molecular Simulations, Inc., Burlington, MA, U.S.A.
36. Available from W. Clark Still, Department of Chemistry, Columbia University, New York, U.S.A..
37. 2 torsional terms, J. Am. Chem. Soc., 99 (1977) 8127.
38. Lam, P.Y.S., Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors, Science, 263 (1994) 380-384.
39. Thaisrivongs, S., Random and Rational: Lead Generation via Rational Drug Design and Combinatorial Chemistry, New York, 19-20 October 1994.
40. Vacca, J.P., Fitzgerald, P.M.D., Holloway, M.K., Hungate, R.W., Starbuck, K.E., Chen, L.J., Darke, P.L., Anderson, P.S., and Huff, J.R., Conformationally constrained HIV-1 protease inhibitors, Bioorg. Med. Chem. Lett., 4 (1994) 499-504.
41. Ghosh, A.K., Thompson, W.J., Fitzgerald, P.M.D., Culberson, J.C., Axel, M.G., McKee, S.P., Huff, J.R. and Anderson, P.S., Structure-based design of HIV-1 protease inhibitors: Replacement of two amides and a 10Π-aromatic system by a fused bis-tetrahydrofuran, J. Med. Chem., 37 (1994) 2506-2508.
42. Chen, Z., Li, Y., Chen, E., Hall, D.L., Darke, P.L, Culberson, J.C., Shafer, J. and Kuo, L.C., Crystal structure at 1.9-A resolution of human immunodeficiency virus (HlV) II protease complexed with L-735,524; An orally bioavailable inhibitor of the HIV protease, J. Biol. Chem., 269 (1994) 26344-26348.